Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy.
Two novel classes of medications are currently under extensive investigation for the treatment of dry age-related macular degeneration (AMD). Emixustat, an orally administered visual cycle inhibitor, and lampalizumab, an intravitreally administered monoclonal body directed against complement factor D, have shown promise in phase 2 clinical trials in the treatment of nonneovascular (dry) AMD. Lampalizumab is currently being evaluated in a large, multicenter, phase 3 clinical trial for dry AMD - geographic atrophy.
Loren S
LS
Jack
Mohammad Ali
MA
Sadiq
Diana V
DV
Do
Quan Dong
QD
Nguyen
D000284:Administration, Oral; D002986:Clinical Trials as Topic; D057092:Geographic Atrophy / Q000188:drug therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D058449:Intravitreal Injections; D010647:Phenyl Ethers / Q000008:administration & dosage / Q000627:therapeutic use*; D011412:Propanolamines / Q000008:administration & dosage / Q000627:therapeutic use*
D007140:Immunoglobulin Fab Fragments; D010647:Phenyl Ethers; D011412:Propanolamines; C000592692:emixustat; C000603963:lampalizumab